Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response.

Skeate JG, Da Silva DM, Chavez-Juan E, Anand S, Nuccitelli R, Kast WM.

PLoS One. 2018 Jan 11;13(1):e0191311. doi: 10.1371/journal.pone.0191311. eCollection 2018.


Human papilloma virus vaccine for low and middle income countries: A step too soon?

Jindal HA, Kaur A, Murugan S.

Hum Vaccin Immunother. 2017 Nov 2;13(11):2723-2725. doi: 10.1080/21645515.2017.1358837. Epub 2017 Aug 28.


Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy.

Mennini FS, Bonanni P, Bianic F, de Waure C, Baio G, Plazzotta G, Uhart M, Rinaldi A, Largeron N.

Cost Eff Resour Alloc. 2017 Jul 11;15:11. doi: 10.1186/s12962-017-0073-8. eCollection 2017.


Endocervical Carcinogenesis and HPV Vaccination: An Occasional Circumstance or a Gap in the Chain?

Makris GM, Karakitsos P, Kotsifa E, Margari N, Poulakaki N, Sergentanis TN, Battista MJ, Chrelias C, Papantoniou N.

Case Rep Obstet Gynecol. 2017;2017:4976741. doi: 10.1155/2017/4976741. Epub 2017 Jan 1.


Estimation of utility weights for human papilloma virus-related health states according to disease severity.

Ock M, Park JY, Son WS, Lee HJ, Kim SH, Jo MW.

Health Qual Life Outcomes. 2016 Nov 28;14(1):163.


Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.

Mesher D, Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JM, Chow EP, Cummings T, Drolet M, Fairley CK, Garland SM, Kahn JA, Kavanagh K, Markowitz L, Pollock KG, Söderlund-Strand A, Sonnenberg P, Tabrizi SN, Tanton C, Unger E, Thomas SL.

Emerg Infect Dis. 2016 Oct;22(10):1732-40. doi: 10.3201/eid2210.160675. Review.


Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.

Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmerón J, Chow SN, Apter D, Castellsagué X, Teixeira JC, Skinner SR, Hedrick J, Limson G, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Del Rosario-Raymundo MR, Catteau G, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Int J Cancer. 2016 Dec 15;139(12):2812-2826. doi: 10.1002/ijc.30391. Epub 2016 Sep 9.


Concordance of adolescent human papillomavirus vaccination parental report with provider report in the National Immunization Survey-Teen (2008-2013).

Hirth J, Kuo YF, Laz TH, Starkey JM, Rupp RE, Rahman M, Berenson AB.

Vaccine. 2016 Aug 17;34(37):4415-21. doi: 10.1016/j.vaccine.2016.07.014. Epub 2016 Jul 18.


Oral sex and oropharyngeal cancer: The role of the primary care physicians.

Nguyen NP, Nguyen LM, Thomas S, Hong-Ly B, Chi A, Vos P, Karlsson U, Vinh-Hung V; International Geriatric Radiation Oncology Group.

Medicine (Baltimore). 2016 Jul;95(28):e4228. doi: 10.1097/MD.0000000000004228. Review.


National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States.

Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, Bauch CT, Galvani AP.

Proc Natl Acad Sci U S A. 2016 May 3;113(18):5107-12. doi: 10.1073/pnas.1515528113. Epub 2016 Apr 18.


Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.

Boiron L, Joura E, Largeron N, Prager B, Uhart M.

BMC Infect Dis. 2016 Apr 16;16:153. doi: 10.1186/s12879-016-1483-5.


Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline.

Min KJ, Kwon SH, Kim S, Kim HJ, Seong SJ, Song YJ, Shin JW, Lee KH, Lim MC, Chung HH, Ju W, Hong JH, Lee JW, Kim JW, Bae DS, Lee JK.

J Gynecol Oncol. 2016 May;27(3):e30. doi: 10.3802/jgo.2016.27.e30. Review.


No evidence that HPV vaccination leads to sexual risk compensation.

Hansen BT.

Hum Vaccin Immunother. 2016 Jun 2;12(6):1451-3. doi: 10.1080/21645515.2016.1158367. Epub 2016 Mar 22.


Self-reported human papillomavirus vaccination does not have an impact on the risk for high-grade cervical intraepithelial neoplasia among women referred for colposcopy.

Kuroki LM, Binder PS, Powell MA, Massad LS, Gao F.

Am J Obstet Gynecol. 2016 Jul;215(1):123-6. doi: 10.1016/j.ajog.2016.02.053. Epub 2016 Mar 2. No abstract available.


Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.

Puthanakit T, Huang LM, Chiu CH, Tang RB, Schwarz TF, Esposito S, Frenette L, Giaquinto C, McNeil S, Rheault P, Durando P, Horn M, Klar M, Poncelet S, De Simoni S, Friel D, De Muynck B, Suryakiran PV, Hezareh M, Descamps D, Thomas F, Struyf F.

J Infect Dis. 2016 Aug 15;214(4):525-36. doi: 10.1093/infdis/jiw036. Epub 2016 Feb 3.


Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.

Skeate JG, Woodham AW, Einstein MH, Da Silva DM, Kast WM.

Hum Vaccin Immunother. 2016 Jun 2;12(6):1418-29. doi: 10.1080/21645515.2015.1136039. Epub 2016 Feb 2. Review.


Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV.

Di Mario S, Basevi V, Lopalco PL, Balduzzi S, D'Amico R, Magrini N.

J Immunol Res. 2015;2015:435141. doi: 10.1155/2015/435141. Epub 2015 Aug 25. Review. Erratum in: J Immunol Res. 2017;2017:4583487.


Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions.

Cornall AM, Roberts JM, Molano M, Machalek DA, Phillips S, Hillman RJ, Grulich AE, Jin F, Poynten IM, Templeton DJ, Garland SM, Tabrizi SN; SPANC Study Team.

BMJ Open. 2015 Aug 26;5(8):e008439. doi: 10.1136/bmjopen-2015-008439.


Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus.

Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK.

J Clin Med. 2015 Apr 3;4(4):614-33. doi: 10.3390/jcm4040614. Review.


Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.

Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, Schulze K, Hillemanns P, Suryakiran P, Thomas F, Struyf F.

Hum Vaccin Immunother. 2016;12(1):20-9. doi: 10.1080/21645515.2015.1065363. Epub 2015 Jul 15.

Supplemental Content

Support Center